Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 5Unknown 1Terminated 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1

Interventions

Specimen Handling 17Biopsy 12Magnetic Resonance Spectroscopy 10Cyclophosphamide 9venetoclax 5Etoposide 4Azacitidine 4fludarabine phosphate 3fludarabine 3durvalumab 3X-Rays 3Tacrolimus 3Paclitaxel 3Interleukin-2 3Gemcitabine 3Cisplatin 3Carboplatin 3zanubrutinib 2prednylidene 2deltacortene 2aldesleukin 2Vincristine 2Taxes 2Stem Cell Transplantation 2Rituximab 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Protein Subunit Vaccines 2Prednisone 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Suspended × gedatolisib × Clear all
NCT03065062 2026-02-13

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Suspended
75 enrolled
GastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡